Patents by Inventor Anthony M. Manning

Anthony M. Manning has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220274778
    Abstract: Automated cold storage unit and systems for storing, monitoring, and maintaining a supply of temperature sensitive pharmaceutical and/or other products in compliance with regulatory requirements are provided. Such units contain an array of independently addressable holding locations for containers with product in one or more controlled temperature zones fitted with temperature sensors. The units include a reader to track product information and status. Product movement within the unit is performed by a computer-controlled robot. A user interface device, preferably in communication with an application service provider to provide remotely managed inventory management and other services, provides users with secure access to the contents of the unit and associated product data and information.
    Type: Application
    Filed: October 7, 2020
    Publication date: September 1, 2022
    Applicant: TruMed Systems, Inc.
    Inventors: Robert James MANNING, Eugene Abraham BAKER, Kevin Lee BOKELMAN, Daniel KLINE, George M. WOHLHIETER, Anthony David BARGHINI, Wesly Hardin BILLMAN, Dan J. DULL, Nicholas James SNYDER, Mark MAJETTE
  • Patent number: 8263326
    Abstract: Compositions and methods for modulating the activation of nuclear factor ?B (NF-?B) are provided. The compositions comprise one or more agents that modulate ubiquitination of phosphorylated I?B? and/or I?B?. Such compositions may be used for treating diseases associated with NF-?B activation. Modulating agents include human E3 ubiquitin ligases, antibodies thereto and variants thereof, as well as related proteins.
    Type: Grant
    Filed: August 8, 2008
    Date of Patent: September 11, 2012
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Anthony M. Manning, Frank Mercurio, Sharon Amit, Yinon Ben-Neriah, Matti Davis, Ada Hatzubai, Avraham Yaron, Irit Alkalay, Aaron Ciechanover
  • Publication number: 20090233855
    Abstract: Compositions and methods for modulating the activation of nuclear factor ?B (NF-?B) are provided. The compositions comprise one or more agents that modulate ubiquitination of phosphorylated I?B? and/or I?B? Such compositions may be used for treating diseases associated with NF-?B activation. Modulating agents include human E3 ubiquitin ligases, antibodies thereto and variants thereof, as well as related proteins.
    Type: Application
    Filed: August 8, 2008
    Publication date: September 17, 2009
    Inventors: Anthony M. MANNING, Frank Mercurio, Sharon Amit, Yinon Ben-Neriah, Matti Davis, Ada Hatzubai, Avraham Yaron, Irit Alkalay, Aaron Ciechanover
  • Patent number: 7414120
    Abstract: Compositions and methods for modulating the activation of nuclear factor ?B (NF-?B) are provided. The compositions comprise one or more agents that modulate ubiquitination of phosphorylated I?B? and/or I?B?. Such compositions may be used for treating diseases associated with NF-?B activation. Modulating agents include human E3 ubiquitin ligases, antibodies thereto and variants thereof, as well as related proteins.
    Type: Grant
    Filed: January 25, 2007
    Date of Patent: August 19, 2008
    Assignee: Signal Pharmaceuticals
    Inventors: Anthony M. Manning, Frank Mercurio, Sharo Amit, Yinon Ben-Neriah, Matti Davis, Ada Hatzubai, Avraham Yaron, Irit Alkalay, Aaron Ciechanover
  • Patent number: 7335676
    Abstract: This invention generally relates to methods for treating or preventing an inflammatory disease or disorder comprising administering to a patient in need thereof an effective amount of a Pyrazoloanthrone Derivative having the following structure: or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are as defined herein.
    Type: Grant
    Filed: December 16, 2003
    Date of Patent: February 26, 2008
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Brydon L. Bennett, Shripad S. Bhagwat, Anthony M. Manning, Brion W. Murray, Eoin C. O'Leary, Yoshitaka Satoh
  • Patent number: 7186503
    Abstract: Compositions and methods for modulating the activation of nuclear factor ?B (NF-?B) are provided. The compositions comprise one or more agents that modulate ubiquitination of phosphorylated I?B? and/or I?B?. Such compositions may be used for treating diseases associated with NF-?B activation. Modulating agents include human E3 ubiquitin ligases, antibodies thereto and variants thereof, as well as related proteins.
    Type: Grant
    Filed: September 19, 2003
    Date of Patent: March 6, 2007
    Assignee: Signal Pharmaceuticals LLC
    Inventors: Anthony M. Manning, Frank Mercurio, Sharo Amit, Yinon Ben-Neriah, Matti Davis, Ada Hatzubai, Avraham Yaron, Irit Alkalay, Aaron Ciechanover
  • Patent number: 7119114
    Abstract: Compounds having activity as selective inhibitors of JNK are disclosed The compounds of this invention are pyrazoloanthrone and derivatives thereof having the following structure: wherein R1 and R2 are as defined herein. Such compounds have utility in the treatment of a wide range of conditions that are responsive to JNK inhibition. Thus, methods of treating such conditions are also disclosed, as are pharmaceutical compositions containing one or more compounds of the above compounds.
    Type: Grant
    Filed: August 18, 2000
    Date of Patent: October 10, 2006
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Brydon L. Bennett, Shripad S. Bhagwat, Anthony M. Manning, Brion W. Murray, Eoin C. O'Leary, Yoshitaka Satoh
  • Publication number: 20040203098
    Abstract: Compositions and methods for modulating the activation of nuclear factor &kgr;B (NF-&kgr;B) are provided. The compositions comprise one or more agents that modulate ubiquitination of phosphorylated I&kgr;B&agr; and/or I&kgr;B&bgr;. Such compositions may be used for treating diseases associated with NF-&kgr;B activation. Modulating agents include human E3 ubiquitin ligases, antibodies thereto and variants thereof, as well as related proteins.
    Type: Application
    Filed: September 19, 2003
    Publication date: October 14, 2004
    Inventors: Anthony M. Manning, Frank Mercurio, Sharon Amit, Yinon Ben-Neriah, Matti Davis, Ada Hatzubai, Avraham Yaron, Irit Alkalay, Aaron Ciechanover
  • Publication number: 20040176434
    Abstract: This invention generally relates to methods for treating or preventing an inflammatory disease or disorder comprising administering to a patient in need thereof an effective amount of a Pyrazoloanthrone Derivative having the following structure: 1
    Type: Application
    Filed: December 16, 2003
    Publication date: September 9, 2004
    Inventors: Brydon L. Bennett, Shripad S. Bhagwat, Anthony M. Manning, Brion W. Murray, Eoin C. O'Leary, Yoshitaka Satoh
  • Publication number: 20040072888
    Abstract: This invention generally relates to methods for treating or preventing an inflammatory disease or disorder comprising administering to a patient in need thereof an effective amount of a Pyrazoloanthrone Derivative having the following structure: 1
    Type: Application
    Filed: March 24, 2003
    Publication date: April 15, 2004
    Inventors: Brydon L. Bennett, Shripad S. Bhagwat, Anthony M. Manning, Brion W. Murray, Eoin C. O'Leary, Yoshitaka Satoh
  • Patent number: 6656713
    Abstract: Compositions and methods for modulating the activation of nuclear factor &kgr;B (NF-&kgr;B) are provided. The compositions comprise one or more agents that modulate ubiquitination of phosphorylated I&kgr;B&agr; and/or I&kgr;B&bgr;. Such compositions may be used for treating diseases associated with NF-&kgr;B activation. Modulating agents include human E3 ubiquitin ligases, antibodies thereto and variants thereof, as well as related proteins.
    Type: Grant
    Filed: April 9, 2001
    Date of Patent: December 2, 2003
    Assignee: Signal Pharmaceuticals, Inc.
    Inventors: Anthony M. Manning, Frank Mercurio, Sharon Amit, Yinon Ben-Neriah, Matti Davis, Ada Hatzubai, Avraham Yaron, Irit Alkalay, Aaron Ciechanover
  • Publication number: 20030166587
    Abstract: Compositions and methods for modulating the activation of nuclear factor &kgr;B (NF-&kgr;B) are provided. The compositions comprise one or more agents that modulate ubiquitination of phosphorylated I&kgr;B&agr; and/or I&kgr;B&bgr;. Such compositions may be used for treating diseases associated with NF-&kgr;B activation. Modulating agents include human E3 ubiquitin ligases, antibodies thereto and variants thereof, as well as related proteins.
    Type: Application
    Filed: April 9, 2001
    Publication date: September 4, 2003
    Inventors: Anthony M. Manning, Frank Mercurio, Sharon Amit, Yinon Ben-Neriah, Matti Davis, Ada Hatzubai, Avraham Yaron, Irit Alkalay, Aaron Ciechanover